Navigation Links
Verenium Corporation to Announce First Quarter 2011 Financial Results
Date:5/5/2011

SAN DIEGO, May 5, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it will release 2011 first quarter financial results on Thursday, May 12, 2011 after market close. In conjunction with the release, the Company will host a conference call with live webcast on Thursday, May 12 at 5:00 p.m. ET.

The call may be accessed by dialing 877-755-7422 (domestic) or 678-894-3067 (international) five minutes prior to start time and providing the passcode 62960243.  A link to the live webcast may be accessed by visiting the "Investors" section of the Company's website at http://www.verenium.com.  A replay of the event will be available on the Company's website approximately two hours after the call and will be archived for 30 days.

About VereniumVerenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

Forward-Looking StatementsStatements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2010 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.Contacts:Kelly Lindenboom

Sarah CarmodyVice President, Corporate Communications

Manager, Corporate Communications858-431-8580

858-431-8581kelly.lindenboom@verenium.com

sarah.carmody@verenium.com
'/>"/>

SOURCE Verenium Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Verenium Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2010
2. Verenium Announces Changes in Senior Management
3. Verenium Announces 2010 Business Update and Outlook for 2011
4. Volcano Corporation to Supply Intravascular Ultrasound Technology to Covidien for Integration with Plaque Excision Systems
5. Volcano Corporation Presentation at Bank of America Merrill Lynch Conference to be Webcast
6. CryoLife Completes Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation
7. ShangPharma Corporation Files 2010 Annual Report on Form 20-F
8. Generex Biotechnology Corporation CEO to Present Live, Online at RetailInvestorConferences.com on May 5th
9. Volcano Corporation Presentation at JMP Securities Conference to be Webcast
10. United Therapeutics Corporation Reports First Quarter 2011 Financial Results
11. Protect Pharmaceutical Corporation Appoints Chief Executive Officer and Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... This morning,s research on ... The Medicines Co. (NASDAQ: MDCO), Ironwood Pharmaceuticals Inc. ... Supernus Pharmaceuticals Inc. (NASDAQ: SUPN ). ... which is governed by the same governing framework ... industry are wholesalers, retailers, pharmacies, and benefit managers. Learn ...
(Date:3/28/2017)... , March 28, 2017  AcelRx Pharmaceuticals, ... on the development and commercialization of innovative therapies ... that the European Medicines Agency (EMA) has notified ... 30 mcg) Marketing Authorisation Application (MAA) has passed ... MAA is underway. The MAA for ARX-04 (known ...
(Date:3/28/2017)... FRANCISCO , March 28, 2017 ...  is expected to reach a value of USD 4.5 ... Grand View Research, Inc. Proper closure of injured tissues ... structure and function. Postoperative leakages occur in 3% to ... complication. They are responsible for one third of postoperative ...
Breaking Medicine Technology:
(Date:3/28/2017)... Square, PA (PRWEB) , ... March 28, 2017 , ... ... online and across a variety of business channels. , While many results are ... of any public relations program. , When it comes to measurement, firms should ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Silicon Valley Hair ... to announce a new blog post about women’s hair loss. Although hair transplant procedures ... loss as they age. Menopause or genetics can be two reasons a woman may ...
(Date:3/28/2017)... ... 28, 2017 , ... Nurse practitioners and physician assistants are ... in the healthcare workforce, according to a survey recently released by PracticeMatch ... candidate leads to healthcare employers of physicians and advanced practice clinicians. , Only ...
(Date:3/27/2017)... CO (PRWEB) , ... March 27, 2017 , ... New ... Mark Braasch for leading sleep apnea treatment, with or without a referral. Sleep apnea ... condition, which can include daytime sleepiness, morning headaches and chronic snoring. , Dr. ...
(Date:3/27/2017)... ... 2017 , ... New patients who want to experience the benefits of ... them placed by Dr. Manju Kejriwal, with or without a referral. Dr. Kejriwal is ... accuracy of each dental implant placement. The i-CAT CBCT system captures the shapes of ...
Breaking Medicine News(10 mins):